| Identification | Back Directory | [Name]
Lefamulin | [CAS]
1061337-51-6 | [Synonyms]
BC 3781
Lefamulin
Lefamulin(BC-3781)
2-[[(1R,2R,4R)-4-Amino-2-hydroxycyclohexyl]thio]acetic acid (3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyldecahydro-5-hydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propano-3aH-cyclopentacycloocten-8-yl ester
Acetic acid, 2-[[(1R,2R,4R)-4-amino-2-hydroxycyclohexyl]thio]-, (3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyldecahydro-5-hydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propano-3aH-cyclopentacycloocten-8-yl ester | [Molecular Formula]
C28H45NO5S | [MDL Number]
MFCD28963989 | [MOL File]
1061337-51-6.mol | [Molecular Weight]
507.73 |
| Chemical Properties | Back Directory | [Boiling point ]
618.6±55.0 °C(Predicted) | [density ]
1.19±0.1 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMF: 16 mg/mL; DMSO: 12 mg/mL; Ethanol: 3 mg/mL; PBS (pH 7.2): 0.25 mg/mL | [form ]
A solid | [pka]
14.45±0.60(Predicted) | [color ]
White to off-white | [InChIKey]
KPVIXBKIJXZQJX-FCEONZPQSA-N | [SMILES]
C(O[C@@H]1C[C@](C=C)(C)[C@@H](O)[C@H](C)[C@@]23CC[C@@H](C)[C@]1(C)[C@]2([H])C(=O)CC3)(=O)CS[C@@H]1CC[C@@H](N)C[C@H]1O |
| Hazard Information | Back Directory | [Uses]
Lefamulin is an antibiotic medication used in the treatment of adults with community-acquired bacterial pneumonia. | [Biological Activity]
Lefamulin inhibits bacterial protein synthesis by binding to the 50S subunit of the bacterial ribosome. Specificallyit binds to the peptidyl transferase center of the ribosome and inhibits the transfer of amino acids to growing polypeptide chainswhich leads to the inhibition of bacterial protein synthesis and bacterial death. Lefamulin is active against a wide range of Gram-positive bacteriaincluding Streptococcus pneumoniaeStaphylococcus aureusand methicillin-resistant S. aureus (MRSA)as well as some atypical bacteria such as Legionella species. It has also been shown to have activity against some Gram-negative bacteriaincluding Haemophilus influenzae and Moraxella catarrhalis. | [Synthesis]
synthesis route of Lefamulin
 | [in vivo]
Lefamulin (10-140 mg/kg, s.c.) shows anti-inflammatory effect on LPS-induced lung neutrophilia mouse model[4].
Lefamulin (1.25-160 mg/kg, s.c.) shows antibacterial effect in S. pneumoniae or S. aureus challenged lung infection mice[5].
| Animal Model: | LPS-induced lung neutrophilia mouse model[4] | | Dosage: | 10-140 mg/kg | | Administration: | Subcutaneous injection (s.c.) | | Result: | Reduced BALF neutrophil cell counts.
Reduced pro-inflammatory cytokine (TNF-α, IL-6, IL-1β, and GM-CSF), chemokine (CXCL-1, CXCL-2, and CCL-2) and MMP-9 levels in mouse lung tissue.
|
|
|
|